0000899243-15-002558.txt : 20150806
0000899243-15-002558.hdr.sgml : 20150806
20150806162851
ACCESSION NUMBER: 0000899243-15-002558
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150804
FILED AS OF DATE: 20150806
DATE AS OF CHANGE: 20150806
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aegerion Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001338042
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 202960116
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE MAIN STREET
STREET 2: SUITE 800
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: (617) 500-7867
MAIL ADDRESS:
STREET 1: ONE MAIN STREET
STREET 2: SUITE 800
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Aegerion Pharmaceuticals Inc
DATE OF NAME CHANGE: 20050906
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Carter Martha J.
CENTRAL INDEX KEY: 0001213040
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34921
FILM NUMBER: 151033547
MAIL ADDRESS:
STREET 1: C/O AEGERION PHARMACEUTICALS, INC.
STREET 2: 89 HEADQUARTERS PLAZA, SUITE 1212
CITY: MORRISTOWN
STATE: NJ
ZIP: 07960
FORMER NAME:
FORMER CONFORMED NAME: CARTER MARTHA J
DATE OF NAME CHANGE: 20030106
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2015-08-04
0
0001338042
Aegerion Pharmaceuticals, Inc.
AEGR
0001213040
Carter Martha J.
C/O AEGERION PHARMACEUTICALS, INC.
ONE MAIN STREET, SUITE 800
CAMBRIDGE
MA
02142
0
1
0
0
See Remarks
Stock Option (right to buy)
19.52
2015-08-04
4
A
0
40000
0.00
A
2025-08-04
Common Stock
40000
40000
D
The stock option award was made to the Reporting Person as part of a retention arrangement approved by the Issuer's Board of Directors on August 4, 2015.
The stock option award has an exercise price equal to the fair market value of the closing price of the Issuer on the date of the grant.
25% of the shares of common stock underlying this stock option award will vest on August 4, 2016. The remaining 75% of the shares of common stock underlying this stock option award will vest thereafter in equal monthly installments through August 4, 2019, subject to the Reporting Person's continued employment with the Issuer.
Chief Regulatory Officer and Senior Vice President
/s/ Jennifer Fitzpatrick, as attorney-in-fact
2015-08-06